WWW.JNEUROSCI.ORG
-
The Journal of Neuroscience Fine Science Tools - Extraordinary Craftsmanship
 QUICK SEARCH:   [advanced]


     
-


HOME
  |  
SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (98)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Richardson, J. D.
Right arrow Articles by Hargreaves, K. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Richardson, J. D.
Right arrow Articles by Hargreaves, K. M.

 Previous Article  |  Next Article 

The Journal of Neuroscience, January 1, 1998, 18(1):451-457

Hypoactivity of the Spinal Cannabinoid System Results in NMDA-Dependent Hyperalgesia

Jennelle Durnett Richardson1, Lin Aanonsen3, and Kenneth M. Hargreaves1, 2

Departments of 1 Pharmacology and 2 Restorative Sciences, University of Minnesota, Minneapolis, Minnesota 55455, and 3 Department of Biology, Macalester College, St. Paul, Minnesota 55105

Cannabinoids, such as Delta 9-THC, are capable of inhibiting nociception, i.e., pain transmission, at least in part, by interacting with spinal Gi/Go-coupled cannabinoid receptors. What is not known, however, is the antinociceptive role of endogenous spinal cannabinoids. If endogenous cannabinoids modulate basal nociceptive thresholds, then alterations in this system could be involved in the etiology of certain pain states. In this report we provide evidence for tonic modulation of basal thermal nociceptive thresholds by the spinal cannabinoid system. Administration of oligonucleotides directed against CB1 cannabinoid receptor mRNA significantly reduced spinal cannabinoid binding sites and produced significant hyperalgesia when compared with a randomer oligonucleotide control. A second method used to reduce activity of the spinal cannabinoid receptor was intrathecal administration of the cannabinoid receptor antagonist SR 141716A. SR 141716A evoked thermal hyperalgesia with an ED50 of 0.0012 fmol. The SR 141716A-induced hyperalgesia was dose-dependently blocked by the administration of D-AP-5 or MK-801, two antagonists to the NMDA receptor. These results indicate that there is tonic activation of the spinal cannabinoid system under normal conditions. Furthermore, hypoactivity of the spinal cannabinoid system results in an NMDA-dependent hyperalgesia and thus may participate in the etiology of certain chronic pain states.

Key words: endogenous cannabinoid; SR 141716A; glutamate; NMDA; hyperalgesia; nociceptive threshold; tonic; spinal cord


Copyright © 1998 Society for Neuroscience  0270-6474/98/181451-07$05.00/0


This article has been cited by other articles:


Home page
Physiol. Rev.Home page
M. Kano, T. Ohno-Shosaku, Y. Hashimotodani, M. Uchigashima, and M. Watanabe
Endocannabinoid-Mediated Control of Synaptic Transmission
Physiol Rev, January 1, 2009; 89(1): 309 - 380.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
M. D. Jhaveri, D. Richardson, D. A. Kendall, D. A. Barrett, and V. Chapman
Analgesic Effects of Fatty Acid Amide Hydrolase Inhibition in a Rat Model of Neuropathic Pain
J. Neurosci., December 20, 2006; 26(51): 13318 - 13327.
[Abstract] [Full Text] [PDF]


Home page
J. Neurophysiol.Home page
C. Liu and J. M. Walker
Effects of a Cannabinoid Agonist on Spinal Nociceptive Neurons in a Rodent Model of Neuropathic Pain
J Neurophysiol, December 1, 2006; 96(6): 2984 - 2994.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
P. Pacher, S. Batkai, and G. Kunos
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pharmacol. Rev., September 1, 2006; 58(3): 389 - 462.
[Abstract] [Full Text] [PDF]


Home page
J PsychopharmacolHome page
M. J. Khodayar, B. Shafaghi, N. Naderi, and M.-R. Zarrindast
Antinociceptive effect of spinally administered cannabinergic and 2-adrenoceptor drugs on the formalin test in rat: possible interactions
J Psychopharmacol, January 1, 2006; 20(1): 67 - 74.
[Abstract] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. M. Rawls, A. Cowan, R. J. Tallarida, E. B. Geller, and M. W. Adler
N-Methyl-D-aspartate Antagonists and WIN 55212-2 [4,5-Dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6H-pyrrolo[3,2,1-i,j]quinolin-6-one], a Cannabinoid Agonist, Interact to Produce Synergistic Hypothermia
J. Pharmacol. Exp. Ther., October 1, 2002; 303(1): 395 - 402.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. A. Varvel and A. H. Lichtman
Evaluation of CB1 Receptor Knockout Mice in the Morris Water Maze
J. Pharmacol. Exp. Ther., June 1, 2002; 301(3): 915 - 924.
[Abstract] [Full Text] [PDF]


Home page
J. Neurophysiol.Home page
V. Morisset and L. Urban
Cannabinoid-Induced Presynaptic Inhibition of Glutamatergic EPSCs in Substantia Gelatinosa Neurons of the Rat Spinal Cord
J Neurophysiol, July 1, 2001; 86(1): 40 - 48.
[Abstract] [Full Text] [PDF]


Home page
GutHome page
D McCarthy
Prostaglandins, COX-2, and sensory perception
Gut, December 1, 2000; 47(90004): iv66 - 68.
[Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
B. R. Martin, I. Beletskaya, G. Patrick, R. Jefferson, R. Winckler, D. G. Deutsch, V. Di Marzo, O. Dasse, A. Mahadevan, and R. K. Razdan
Cannabinoid Properties of Methylfluorophosphonate Analogs
J. Pharmacol. Exp. Ther., September 1, 2000; 294(3): 1209 - 1218.
[Abstract] [Full Text]


Home page
EndocrinologyHome page
D. Melck, L. De Petrocellis, P. Orlando, T. Bisogno, C. Laezza, M. Bifulco, and V. Di Marzo
Suppression of Nerve Growth Factor Trk Receptors and Prolactin Receptors by Endocannabinoids Leads to Inhibition of Human Breast and Prostate Cancer Cell Proliferation
Endocrinology, January 1, 2000; 141(1): 118 - 126.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. M. Walker, S. M. Huang, N. M. Strangman, K. Tsou, and M. C. Sanudo-Pena
Pain modulation by release of the endogenous cannabinoid anandamide
PNAS, October 12, 1999; 96(21): 12198 - 12203.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
A. Zimmer, A. M. Zimmer, A. G. Hohmann, M. Herkenham, and T. I. Bonner
Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice
PNAS, May 11, 1999; 96(10): 5780 - 5785.
[Abstract] [Full Text] [PDF]


Home page
J. Neurophysiol.Home page
A. G. Hohmann, K. Tsou, and J. M. Walker
Cannabinoid Suppression of Noxious Heat-Evoked Activity in Wide Dynamic Range Neurons in the Lumbar Dorsal Horn of the Rat
J Neurophysiol, February 1, 1999; 81(2): 575 - 583.
[Abstract] [Full Text] [PDF]



-

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help

-
Copyright 2009 by Society for Neuroscience ONLINE ISSN: 1529-2401
-